← Leaderboards
Craig Lindsley
Vanderbilt University
$38,671,033
Attributed
$44,486,559
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.9M · FY2008–24$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$77,938,796 · 20
By mechanism
U54$42,440,480 · 5
R01$13,915,694 · 7
U01$12,471,501 · 2
U19$6,204,425 · 3
UG3$1,585,635 · 1
S10$670,818 · 1
Top collaborators
- Colleen M Niswender11 shared
- P Jeffrey Conn10 shared
- Robert W Gereau5 shared
- Jerri Michelle Rook5 shared
- Kevin D Niswender4 shared
- Carrie Kimberly Jones3 shared
- John Scott Daniels1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- F Peter Guengerich$48,178,939
- Michael P Stone$20,424,729
- P Jeffrey Conn$37,782,937
- Lawrence J Marnett$28,791,111
- Jerod S Denton$12,278,378
Others in their field
Top investigators on “Pharmacology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$244,272,171
- Constance Ann Benson · University Of California, San Diego$243,271,751
- Daniel R Kuritzkes · Brigham And Women'S Hospital$211,464,839
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$173,041,343
- Garret A Fitzgerald · University Of Pennsylvania$142,571,551
- David Heimbrook · Leidos Biomedical Research, Inc.$130,037,760
Research focus
PharmacologyIn VivoBasePharmaceutical ChemistryLeadEnsurePropertyPre-ClinicalReceptorPharmaceutical PreparationsDrug KineticsAdverse EffectsAgonistBrainMolecularSmall MoleculeRodentIn VitroRattusSchizophreniaCoupledDoseProgramsClinical Research
Grant awards (78)
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders$700,523
R01 · FY2024 · MH
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders$697,667
R01 · FY2023 · MH
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2023 · NS
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders$694,870
R01 · FY2022 · MH
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2022 · NS
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$76,619
UH3 · FY2022 · NS
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders$695,079
R01 · FY2021 · MH
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$191,208
UH3 · FY2021 · NS
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders$741,117
R01 · FY2020 · MH
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$1,585,635
UG3 · FY2019 · NS
Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator Probe$399,571
R01 · FY2019 · MH
Development of an mGlu2/4 heterodimer-selective allosteric modulator$464,524
R01 · FY2018 · MH
Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator Probe$400,356
R01 · FY2018 · MH
Safety and tolerability testing of VU0467319: an M1 PAM for clinical development$1,325,033
U19 · FY2017 · MH · contact PI
Development of an mGlu2/4 heterodimer-selective allosteric modulator$516,805
R01 · FY2017 · MH
Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator Probe$400,356
R01 · FY2017 · MH
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$392,500
R01 · FY2017 · MH · contact PI
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$353,142
R01 · FY2017 · DA · contact PI
Safety and tolerability testing of VU0467319: an M1 PAM for clinical development$1,750,895
U19 · FY2016 · MH · contact PI
Fluorescent and Luminescent Kinetic Imaging Plate Reader$670,818
S10 · FY2016 · OD · contact PI
Development of an mGlu2/4 heterodimer-selective allosteric modulator$516,805
R01 · FY2016 · MH
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$392,500
R01 · FY2016 · MH · contact PI
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$349,610
R01 · FY2016 · DA · contact PI
Allosteric modulators of the glucagon-like peptide-1 receptor$168,726
R01 · FY2016 · GM
Allosteric modulators of the glucagon-like peptide-1 receptor$130,267
R01 · FY2016 · GM
M1 PAM Back-up Program and Chemistry Support of the IND$1,712,121
U19 · FY2015 · MH · contact PI
Lead Optimization & Development of Back-Up mGlu5 NAM Candidates for Treatment of$455,265
U19 · FY2015 · MH · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$392,500
R01 · FY2015 · MH · contact PI
Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction$353,142
R01 · FY2015 · DA · contact PI
Allosteric modulators of the glucagon-like peptide-1 receptor$298,170
R01 · FY2015 · GM
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,880,513
U01 · FY2014 · MH
Medicinal Chemistry$633,001
U01 · FY2014 · MH · contact PI
Lead Optimization & Development of Back-Up mGlu5 NAM Candidates for Treatment of$455,264
U19 · FY2014 · MH · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$392,291
R01 · FY2014 · MH · contact PI
Allosteric modulators of the glucagon-like peptide-1 receptor$297,379
R01 · FY2014 · GM
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$2,644,617
U54 · FY2013 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,805,294
U01 · FY2013 · MH
Chemistry Core$1,658,110
U54 · FY2013 · MH · contact PI
Medicinal Chemistry$607,611
U01 · FY2013 · MH · contact PI
Lead Optimization & Development of Back-Up mGlu5 NAM Candidates for Treatment of$505,847
U19 · FY2013 · MH · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$390,000
R01 · FY2013 · MH · contact PI
Administrative Core$94,915
U54 · FY2013 · MH · contact PI
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$3,000,000
U54 · FY2012 · MH · contact PI
Chemistry Core$2,416,147
U54 · FY2012 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,880,515
U01 · FY2012 · MH
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$1,500,000
U54 · FY2012 · MH · contact PI
Medicinal Chemistry$632,846
U01 · FY2012 · MH · contact PI
Administrative Core$500,000
U54 · FY2012 · MH · contact PI
Chemistry Core$500,000
U54 · FY2012 · MH · contact PI
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction$394,370
R01 · FY2012 · DA · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$341,921
R01 · FY2012 · MH · contact PI
Administrative Core$280,396
U54 · FY2012 · MH · contact PI
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$5,188,419
U54 · FY2011 · MH · contact PI
Chemistry Core$3,617,666
U54 · FY2011 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,874,484
U01 · FY2011 · MH
Medicinal Chemistry$630,737
U01 · FY2011 · MH · contact PI
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction$398,616
R01 · FY2011 · DA · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$341,921
R01 · FY2011 · MH · contact PI
Administrative Core$254,804
U54 · FY2011 · MH · contact PI
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$5,056,199
U54 · FY2010 · MH · contact PI
Chemistry Core$3,318,609
U54 · FY2010 · MH · contact PI
Vanderbilt NCDDDG for Discovery of Novel Treatments for Schizophrenia$1,891,522
U01 · FY2010 · MH
Medicinal Chemistry$634,978
U01 · FY2010 · MH · contact PI
Center base project #1$500,000
U54 · FY2010 · MH · contact PI
Center base project #2$500,000
U54 · FY2010 · MH · contact PI
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction$414,928
R01 · FY2010 · DA · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$345,375
R01 · FY2010 · MH · contact PI
Administrative Core$268,223
U54 · FY2010 · MH · contact PI
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$3,991,690
U54 · FY2009 · MH · contact PI
Chemistry Core$1,845,997
U54 · FY2009 · MH · contact PI
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction$425,020
R01 · FY2009 · DA · contact PI
Administrative Core$377,940
U54 · FY2009 · MH · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$345,375
R01 · FY2009 · MH · contact PI
The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development$2,738,984
U54 · FY2008 · MH · contact PI
Chemistry Core$1,803,374
U54 · FY2008 · MH · contact PI
Partial Antagonists of mGluR5 for Treatment of Cocaine Addiction$428,263
R01 · FY2008 · DA · contact PI
Administrative Core$384,390
U54 · FY2008 · MH · contact PI
Selective M1 mAChR allosteric modulators for the treatment of schizophrenia$342,005
R01 · FY2008 · MH · contact PI